{"slideshow_credits": null, "snippet": "Federal authorities are looking into traders who traffic in Herbalife\u2019s stock. | AstraZeneca rejected a sweetened offer by Pfizer. | Ares is set to debut on the public market. | K.K.R. seeks to attract smaller investors.", "abstract": "Federal authorities are looking into traders who traffic in Herbalife\u2019s stock. | AstraZeneca rejected a sweetened offer by Pfizer. | Ares is set to debut on the public market. | K.K.R. seeks to attract smaller investors.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Sydney", "role": "reported", "lastname": "EMBER", "rank": 1, "organization": ""}], "original": "By SYDNEY EMBER"}, "web_url": "http://dealbook.nytimes.com/2014/05/02/morning-agenda-scrutiny-for-traders-of-herbalife/", "lead_paragraph": null, "headline": {"main": "Morning Agenda: Scrutiny for Traders of Herbalife", "kicker": "DealBook"}, "_id": "536387c138f0d84d9e2713cf", "word_count": "1966", "multimedia": [], "pub_date": "2014-05-02T07:54:06Z", "source": "The New York Times", "news_desk": "Business", "keywords": [], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}